Together with the relationship between insulin secretion and lack of efficacy on progression to diabetes, our study suggests that upon removal of ALT therapy prediabetes, benefits on β-cell function are unlikely to be maintained. The gene discussed is GPT; the disease is prediabetes syndrome.